IBRX - ImmunityBio Inc
IEX Last Trade
3.96
0.160 4.040%
Share volume: 2,275,939
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.80
0.16
4.21%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-09 | 2023-03-01 | 2023-05-11 | 2023-08-08 | 2023-11-09 | 2024-03-19 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 317.717 M | 352.943 M | 362.356 M | 343.400 M | 291.227 M | 432.419 M | 504.452 M | 400.679 M | |
| Current Assets | 114.990 M | 143.092 M | 140.577 M | 113.486 M | 66.825 M | 215.082 M | 294.084 M | 195.722 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 30.601 M | 30.547 M | 31.503 M | 20.754 M | 18.846 M | 22.961 M | 25.603 M | 23.090 M | |
| Short Term Investments | 30.601 M | 30.547 M | 31.503 M | 20.754 M | 18.846 M | 22.961 M | 25.603 M | 23.090 M | |
| Total Receivables | 1.451 M | 1.488 M | 1.890 M | 1.464 M | 2.025 M | 2.325 M | 2.019 M | 2.137 M | |
| Current Cash | 82.938 M | 111.057 M | 107.184 M | 91.268 M | 45.954 M | 189.796 M | 266.462 M | 170.495 M | |
| Total Non-current Assets | 202.727 M | 209.851 M | 221.779 M | 229.914 M | 224.402 M | 217.337 M | 210.368 M | 204.957 M | |
| Property Plant Equipment | 119.445 M | 130.441 M | 143.659 M | 154.165 M | 151.487 M | 152.000 M | 146.082 M | 143.517 M | |
| Other Assets | 60.630 M | 58.128 M | 57.277 M | 55.427 M | 53.082 M | 46.053 M | 46.302 M | 44.868 M | |
| Intangible Assets | 21.738 M | 20.471 M | 20.003 M | 19.502 M | 18.992 M | 18.467 M | 17.093 M | 16.572 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 317.717 M | 352.943 M | 362.356 M | 343.400 M | 291.227 M | 432.419 M | 504.452 M | 400.679 M | |
| Total liabilities | 737.532 M | 779.642 M | 809.683 M | 872.383 M | 933.343 M | 844.136 M | 1.091 B | 1.093 B | |
| Total current liabilities | 376.050 M | 70.840 M | 500.861 M | 564.945 M | 613.478 M | 90.324 M | 58.283 M | 53.759 M | |
| Accounts Payable | 18.053 M | 20.237 M | 24.485 M | 33.573 M | 25.488 M | 21.090 M | 10.331 M | 14.965 M | |
| Other liabilities | 290.000 K | 569.000 K | 22.093 M | 18.242 M | 28.272 M | 39.837 M | 415.213 M | 312.618 M | |
| Current long term debt | 301.488 M | 1.365 M | 434.551 M | 474.322 M | 524.496 M | 4.363 M | 5.244 M | 6.082 M | |
| Long term debt | 363.189 M | 710.615 M | 289.222 M | 291.929 M | 294.660 M | 712.903 M | 616.893 M | 725.285 M | |
| Other liabilities | 290.000 K | 569.000 K | 22.093 M | 18.242 M | 28.272 M | 39.837 M | 415.213 M | 312.618 M | |
| Minority interest | -2.159 M | -2.382 M | -2.493 M | -2.733 M | -3.067 M | 1.072 M | 1.050 M | 1.029 M | |
| Total Shareholder equity | -419.815 M | -426.699 M | -447.327 M | -528.983 M | -642.116 M | -411.717 M | -586.987 M | -692.012 M | |
| Common stock | 397.992 M | 400.060 M | 403.668 M | 428.381 M | 437.457 M | 498.375 M | 670.329 M | 672.831 M | |
| Retained earnings | -2.159 B | -2.270 B | -2.378 B | -2.495 B | -2.633 B | -2.728 B | -2.962 B | -3.096 B |